Zypadhera 405 mg inj. susp. verl. afgifte (pdr. + oplosm.) i.m. flac. 405 mg + 3 ml
Active ingredient: Olanzapine
View notice details →News topic
Expected end: 2024-06
All current shortage notices related to Expected end: 2024-06, structured by product, country, active ingredient and reporting period.
3 noticesZypadhera 300 mg inj. susp. verl. afgifte (pdr. + oplosm.) i.m. flac. 300 mg + 3 ml
Active ingredient: Olanzapine
View notice details →Zypadhera 210 mg inj. susp. verl. afgifte (pdr. + oplosm.) i.m. flac. 210 mg + 3 ml
Active ingredient: Olanzapine
View notice details →Plan supply. Connect sourcing and warehousing.
For pharmacies, wholesalers and manufacturers: choose the service matching your operational need.
Improve sourcing and supply availability
Researching this shortage professionally? We assess sourcing routes, suppliers and cross-border supply against your requirements. A notice does not confirm stock availability.
Send a sourcing enquiry →Pharma warehouse and pharmaceutical warehousing in Cheb
Medicine storage, batch and expiry control, picking and distribution for Germany and Europe. We agree the storage profile, temperature and capacity with you.
Request warehouse capacity →